FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

FDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status

horizonal rule

Dockets Management
Dockets Entered On February 15, 2005
Table of Contents
Docket # Title
1999P-1340 Declared Eternity eau de Parfum Misbranded
2000N-0504 Egg Safety Action Plan
2003F-0088 Increase the Maximum Permitted Energy Level of X-rays
2003N-0076 Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
2004D-0460 Guidance for Industry on Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization
2004D-0510 Live & Perishable Fish & Fishery Products for Export to the European Union and the European Free Trade Association
2004N-0355 Scientific Considerations Related to Developing Follow-on Protein Products
2004N-0454 Dietary Supplements; Premarket Notification for New Dietary Ingredient Notifications; Public Meeting
2005D-0033 Guidance for Industry on Internal Radioactive Contamination -- Development of Decorporation Agents
2005D-0042 Draft Guidance on the Open Public Hearing, FDA Advisory Committee Meetings
2005N-0038 Reporting of Adverse Events to Institutional Review Boards; Public Hearing
2005P-0070 ANDA Suitability for Oral Salmon Calcitonin
2005P-0072 Withholding of safety information regarding risks of Steven s Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Ibuprofen products
1999P-1340 Declared Eternity eau de Parfum Misbranded
EMC 580 D. Buckland Vol #: 24
2000N-0504 Egg Safety Action Plan
EMC 1900 R. Steele Vol #: 31
EMC 1901 No signature Vol #: 31
2003F-0088 Increase the Maximum Permitted Energy Level of X-rays
EMC 129 D. Erickson Vol #: 2
EMC 130 Number Not Used Vol #: 2
EMC 131 Number Not Used Vol #: 2
EMC 132 Number Not Used Vol #: 2
EMC 133 V. Levasseur Vol #: 2
EMC 134 D. Shelton Vol #: 2
EMC 135 M. Bess Vol #: 2
EMC 136 Y. Saavedra Vol #: 2
EMC 137 A. Hojnowski Vol #: 2
EMC 138 L. Peck, PhD Vol #: 2
EMC 139 L. Drew Vol #: 2
EMC 140 H. Robertson Vol #: 2
EMC 141 L. Seff Vol #: 2
EMC 142 M. Zwaenepoel Vol #: 2
EMC 143 D. May Vol #: 2
EMC 144 N. Edmonson Vol #: 2
EMC 145 P. Swindells Vol #: 2
EMC 146 P. Starkey Vol #: 2
EMC 147 J. Cross Vol #: 2
EMC 148 H. Pieper Vol #: 2
EMC 149 E. Walker Vol #: 2
EMC 150 D. Palumbo Vol #: 2
EMC 151 S. Tiwald Vol #: 2
EMC 152 S. Shelton Vol #: 2
EMC 153 G. Kenton Vol #: 2
EMC 154 D. Coffin Vol #: 2
EMC 155 W. Woets Vol #: 2
EMC 156 J. Sarstedt Vol #: 2
EMC 157 B. Everson Vol #: 2
EMC 158 M. Lake Vol #: 2
EMC 159 No signature Vol #: 2
EMC 160 W. Hicks Vol #: 2
EMC 161 G. Irizarry Vol #: 2
EMC 162 No signature Vol #: 2
EMC 163 J. Knudsen Vol #: 2
EMC 164 C. and C Garner Vol #: 2
EMC 165 T. Walsh Vol #: 2
EMC 166 M. Glasgow Vol #: 2
EMC 167 T. Bleeke Vol #: 2
EMC 168 S. Proffitt Vol #: 2
EMC 169 J. Lizak Vol #: 2
EMC 170 M. Gaylor Vol #: 2
EMC 171 P. Brenenstahl Vol #: 2
EMC 172 M. Adams Vol #: 2
EMC 173 J. Barr Vol #: 2
EMC 174 V. Gilbert Vol #: 2
EMC 175 D. Cool Vol #: 2
EMC 176 S. Cardella Vol #: 2
EMC 177 H. Jackson Vol #: 2
EMC 178 W. Croce Vol #: 2
EMC 179 I. Miracle Vol #: 2
EMC 180 Dr. Nehrlich Vol #: 2
EMC 181 G. Y=Taylor Vol #: 2
EMC 182 R. Hines Vol #: 2
EMC 183 B. Gibson Vol #: 2
EMC 184 M. Sica Vol #: 2
EMC 185 T. Norton Vol #: 2
EMC 186 R and H McNeill Vol #: 2
EMC 187 J. Meissner Vol #: 2
EMC 188 B. McDermott Vol #: 2
EMC 189 C. Hastings Vol #: 2
EMC 190 C. Dempsey Vol #: 2
EMC 191 R. Levine Vol #: 2
EMC 192 No signature Vol #: 2
EMC 193 Z. DeBrecht Vol #: 2
EMC 194 S. Edmonson Vol #: 2
EMC 195 L. LoCicero Vol #: 2
EMC 196 F. Castellani Vol #: 2
EMC 197 C. Payne Vol #: 2
EMC 198 S. Miller Vol #: 2
EMC 199 S. Best Vol #: 2
EMC 200 K. Bannerman Vol #: 2
EMC 201 B. Boyts Vol #: 2
EMC 202 A. Hill Vol #: 2
EMC 203 M. Dillon Vol #: 2
EMC 204 M. Carroll Vol #: 2
EMC 205 J. Budrevich Vol #: 2
EMC 206 E. Rosenberg Vol #: 2
EMC 207 J. Kleindienst Vol #: 2
EMC 208 K. Barnwell Vol #: 2
EMC 209 R. Lackey Vol #: 2
EMC 210 R. Serenbetz Vol #: 2
EMC 211 D. Quintana Vol #: 2
EMC 212 J. Martin Vol #: 2
EMC 213 H. Koelle Vol #: 2
EMC 214 L. Lassiter Vol #: 2
EMC 215 K. Gilmour Vol #: 2
EMC 216 D. Simmons Vol #: 2
EMC 217 A. Wieland Vol #: 2
EMC 218 W. Russell Vol #: 2
EMC 219 B. Pence Vol #: 2
EMC 220 B. Thompson Vol #: 2
EMC 221 M. Jones Vol #: 2
EMC 222 B. Thompson Vol #: 2
EMC 223 A. Cardenas Vol #: 2
EMC 224 M. Young Vol #: 2
EMC 225 T. Tuffy Vol #: 2
EMC 226 R. Stuve Vol #: 2
EMC 227 J. Wenglin Vol #: 2
EMC 228 M. Frey Vol #: 2
EMC 229 R. Werlink Vol #: 2
EMC 230 E. Collins Vol #: 2
EMC 231 B. Lee Vol #: 2
EMC 232 D. Smith Vol #: 2
EMC 233 A. Hill Vol #: 2
EMC 234 L. Miller Vol #: 2
EMC 235 L. Miller Vol #: 2
EMC 236 E. Elliott Vol #: 2
EMC 237 J. Bart Vol #: 2
EMC 238 K. Lorenzen Vol #: 2
EMC 239 J. Galbraith Jr. Vol #: 2
EMC 240 C. Jentner Vol #: 2
EMC 241 S. Candiani Vol #: 2
EMC 242 K. Heffner Vol #: 2
EMC 243 C. Kane Vol #: 2
EMC 244 C. Simmons Vol #: 2
EMC 245 D. Hart Vol #: 2
EMC 246 Maja Vol #: 2
EMC 247 L. Turley Vol #: 2
EMC 248 C. Smeets Vol #: 2
EMC 249 J. Cronin Vol #: 2
EMC 250 P. Kindersley Vol #: 2
EMC 251 C. Kromann Vol #: 2
EMC 252 M. Golden Vol #: 2
EMC 253 N. Senft Vol #: 2
EMC 254 A. Bates Vol #: 2
EMC 255 L. Lundemo Vol #: 2
EMC 256 D. Helle Vol #: 2
EMC 257 B. Wills Vol #: 2
EMC 258 A. Sutton Vol #: 2
EMC 259 T. Basile Vol #: 2
EMC 260 A. Curtis Vol #: 2
EMC 261 A. Curtis Vol #: 2
EMC 262 B. Buchanan Vol #: 2
EMC 263 W. Mahmmod Vol #: 2
EMC 264 M. Zarones Vol #: 2
EMC 265 S. Dexter Vol #: 2
EMC 266 F. Campbell Vol #: 2
EMC 267 L. Anderson Vol #: 2
EMC 268 N. Daoust Vol #: 2
EMC 269 J. Daoust Vol #: 2
EMC 270 J. Negri Vol #: 2
EMC 271 C. Mizerany Vol #: 2
EMC 272 S. Pinkerton Vol #: 2
EMC 273 D. Rupiper Vol #: 2
EMC 274 A. Puris Vol #: 2
EMC 275 M. Herschler Vol #: 2
EMC 276 C. Norton Vol #: 2
EMC 277 M. Sher Vol #: 2
EMC 278 T. Williams Vol #: 2
EMC 279 L. Caverly Vol #: 2
EMC 280 T. Moore Vol #: 2
EMC 281 J. Riley Vol #: 2
EMC 282 K. Leuenroth Jr. Vol #: 2
EMC 283 E. Ferranti Vol #: 2
EMC 284 K. Brown Vol #: 2
EMC 285 T. Swartz Vol #: 2
EMC 286 C. Judge Vol #: 2
EMC 287 G. Dalton Vol #: 2
EMC 288 J. Sneller Vol #: 2
EMC 289 B. Fabricius Vol #: 2
EMC 290 Darvin Vol #: 2
EMC 291 T. Connor Vol #: 2
2003N-0076 Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
EMC 529 C. Daly Vol #: 9
EMC 530 L. Middleton Vol #: 9
EMC 531 C. Little Vol #: 9
EMC 532 No signature Vol #: 9
EMC 533 B. Trimpey Vol #: 9
2004D-0460 Guidance for Industry on Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization
EMC 1 Apotex, Inc. Vol #: 1
2004D-0510 Live & Perishable Fish & Fishery Products for Export to the European Union and the European Free Trade Association
EMC 5 New England Lobster Exporters Coalition Vol #: 1
2004N-0355 Scientific Considerations Related to Developing Follow-on Protein Products
EMC 7 Hoffman-La Roche, Inc. (Roche) Vol #: 4
2004N-0454 Dietary Supplements; Premarket Notification for New Dietary Ingredient Notifications; Public Meeting
EMC 1100 K. Holmes Vol #: 28
EMC 1101 G. Smith Vol #: 28
EMC 1102 D. Porter Vol #: 28
EMC 1103 J. Harding Vol #: 28
EMC 1104 W. Park Vol #: 28
EMC 1105 O. Bessette Vol #: 28
EMC 1106 J. Postell Vol #: 28
EMC 1107 A. Ross Vol #: 28
EMC 1108 L. Loon Vol #: 28
EMC 1109 L. Loon Vol #: 28
EMC 1110 B. Brown Vol #: 28
EMC 1111 L. Hamlin Vol #: 28
2005D-0033 Guidance for Industry on Internal Radioactive Contamination -- Development of Decorporation Agents
GDL 1 Guidance Vol #: 1
NAD 1 FDA Vol #: 1
2005D-0042 Draft Guidance on the Open Public Hearing, FDA Advisory Committee Meetings
GDL 1 Guidance Vol #: 1
NAD 1 FDA Vol #: 1
2005N-0038 Reporting of Adverse Events to Institutional Review Boards; Public Hearing
EAPE 48 Idanpaan-Heikkila, Juhana Vol #: 1
EAPE 49 Wong, Jennifer Vol #: 1
EAPE 50 Kerwin, Rosemary Vol #: 1
EAPE 51 Queffelec, Denise Vol #: 1
EAPE 52 Howland, Margaret Vol #: 1
EAPE 53 Bankert, Elizabeth Vol #: 1
EAPE 54 Goode, Donald Vol #: 1
EAPE 55 Yonren, Samuel Vol #: 1
2005P-0070 ANDA Suitability for Oral Salmon Calcitonin
ACK 1 HFA-305 Vol #: 1
CP 1 Bone Medical Limited Vol #: 1
2005P-0072 Withholding of safety information regarding risks of Steven s Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Ibuprofen products
ACK 1 HFA-305 to Professor of Surgery, Chief of Plastic Surgery Vol #: 1
CP 1 Professor of Surgery, Chief of Plastic Surgery Vol #: 1

Page created on February 16, 2005 kk

horizonal rule

Dockets Home| Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA | Privacy | Accessibility

FDA/Dockets Management